PreferredStockChannel

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Wed, July 17, 6:21 PM

Slide #2. Sunesis Pharmaceuticals, Inc. Preferred Stock Offering

Company: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Date announced: 7/10/2019
Preferred Stock Offering Details: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, and general corporate purposes.

Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new therapeutics for the treatment of cancer. Co.'s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Co.'s primary program is vecabrutinib, a non-covalent inhibitor of Bruton's Tyrosine Kinase. Co. is also developing SNS-510, a phosphoinositide-dependent kinase-1 inhibitor licensed from Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited.
Open the SNSS Page at Preferred Stock Channel »

Name: 
Sunesis Pharmaceuticals Inc
Website: 
www.sunesis.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding SNSS: 
4 (see which ones)
Total Market Value Held by ETFs: 
$1,975,234
Total Market Capitalization: 
$62,000,000
% of Market Cap. Held by ETFs: 
3.19%
 

Open the SNSS Page at Preferred Stock Channel (in a new window) »

Quotes delayed 20 minutes


Buy (3.00 out of 4)
39th percentile
(ranked lower than approx. 61% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 2 of 462 | www.PreferredStockChannel.com

Copyright © 2010 - 2019, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.